Guardant Health
Scaling a $400M+ Diagnostics Business Through Strategic Market Expansion
When a pioneering cancer testing company needed to expand beyond their initial success, I led a strategy that transformed Guardant Health from a single-product business into a comprehensive testing platform that dramatically expanded their growth potential.
PROBLEM
Despite strong market traction, Guardant's innovative blood-based cancer testing technology was limited to late-stage cancer patients. This constrained their growth potential and competitive position as comprehensive cancer testing was becoming standard practice in oncology.
APPROACH
I shaped their product roadmap to expand across all stages of cancer care and defined a comprehensive brand strategy for their growing product portfolio. I built a world-class marketing organization capable of supporting multiple product launches simultaneously. This included leading the FDA approval strategy for comprehensive liquid biopsy while launching 3 new products, including a tissue comprehensive genomic test, a test for Minimal Residual Disease (MRD), and a test for cancer monitoring.
OUTCOME
Test volume grew 35% quarter-over-quarter while successfully launching three products across early and late-stage cancer applications. We established Guardant as the category leader in blood-based cancer testing, expanding their market from late-stage treatment to include early detection and monitoring, repositioning the company's growth trajectory.